NY-CARESTREAM-HEALTH
20.2.2024 21:42:30 CET | Business Wire | Press release
Carestream Health will exhibit its expanding portfolio of innovative, industry-leading medical imaging solutions at the annual European Congress of Radiology (ECR) from 28th February to 3rd March in Vienna Building on its century-long foundation of imaging research science, the company will showcase its diagnostic imaging solutions that help improve clinical outcomes, enhance the imaging experience for users and patients, and strengthen the financial position of healthcare facilities.
“We understand that the radiology industry across the world is facing challenges such as a shortage of skilled staff and consequently radiologists are dealing with increased workload demands,” said Jane Moverley, International Sales Director, Digital Radiology. “This is why Carestream solutions add significant value to the imaging process. For example, our new DRX-LC Detector helps deliver high-quality, long-length imaging with a single exposure to deliver a more user-friendly workflow, optimize productivity, and ease the physical stress on radiographers. We are also showcasing our expanding line of X-ray solutions that deliver high-quality imaging to meet our customers’ needs at an affordable price.”
Solutions to Help Improve Clinical Outcomes
DRX-Compass X-ray System
- Exceptional image quality
- Scalable and upgradeable technology
- Available in floor-mount or OTC configuration
DRX-Revolution Mobile X-ray System
- Our original X-ray Room on Wheels offering provides superb image quality, maneuverability, and on-board storage.
- Robust functionality with Carestream’s most advanced image processing is available in a single platform.
- Low-profile design and flexibility mean you can easily capture images wherever you need them most.
Solutions to Enhance User and Patient Experience
DRX-LC Detector
- Captures long-length images with a single exposure
- Saves exam time and speeds up workflow
- Decreases retakes
- Allows a higher level of patient comfort
ImageView Software
- Provides high-image quality with AI and advanced image processing technology
- Delivers a quick and sleek operator experience via a single-screen workflow
- Allows users to track analytics on key parameters such as exposure rates and number of rejections
- Provides dose reporting
Solutions to Strengthen Financial Position
New DRX-Rise Mobile X-ray System
- Cutting-edge features in a fully-integrated, digital X-ray unit provide an affordable path to digital imaging.
- Efficiency-boosting features include two touchscreen displays, a state-of-the-art lithium battery, and in-bin detector charging.
- Bedside imaging minimizes disruption and helps deliver an improved patient experience.
DR Detectors
- These are the right detector for every facility, workflow, and budget.
- X-Factor capability lets you share detectors across your facility.
- Upgrade your existing film or CR systems to full wireless DR with a retrofit system and detector.
- Various cassette sizes let you choose the best fit.
Full Suite of Imaging Solutions on Display at ECR 2024
Carestream will also display additional imaging innovations at Expo X2-Booth 220 at ECR. These will include the DRX-Compass X-ray System, DRX-Rise Mobile X-ray System, and DRX-Revolution Mobile X-ray System, as well as our suite of DR Detectors.
Schedule an appointment to discuss Carestream’s latest innovations and other medical imaging solutions at ECR 2024.
About Carestream Health
Carestream is a worldwide provider of medical imaging systems; X-ray imaging systems for non-destructive testing; and precision contract coating services for a wide range of industrial, medical, electronic, and other applications—all backed by a global service and support network. For more information about the company’s broad portfolio of products, solutions, and services, please contact your Carestream representative, or call 1-888-777-2072, or visit www.carestream.com.
CARESTREAM is a trademark of Carestream Health.
“Rx only”
2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240220770604/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom